Quinolines

Details Quinolines Quinolines

2011-04-12

2011-04-12

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S160000

Reexamination Certificate

active

07923561

ABSTRACT:
The present invention relates to 2-Aminoquinoline derivatives of general formula Iand pharmaceutically-acceptable acid-addition salts thereof, wherein R1, R2and X are as defined in the specification. The compounds may be used as 5-HT5Areceptor antagonists. The present invention relates also to processes for making such a compound and a pharmaceutical composition comprising such a compound. Compounds of the present invention are useful in the prevention and/or treatment of anxiety depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders and gastrointestinal disorders.

REFERENCES:
patent: 2007/0202924 (2007-08-01), Lai et al.
patent: 2007/0299074 (2007-12-01), Netz et al.
patent: 2008/0146567 (2008-06-01), Kolczewski et al.
patent: 2009/0227628 (2009-09-01), Kolczewski et al.
patent: WO 01/87845 (2001-11-01), None
patent: 03037872 (2003-05-01), None
patent: WO 03/080579 (2003-10-01), None
patent: 2004034985 (2004-04-01), None
patent: 2004080463 (2004-09-01), None
patent: WO 2004/096771 (2004-11-01), None
patent: WO 2004/106305 (2004-12-01), None
patent: WO 2005/082871 (2005-09-01), None
patent: WO 2006/103511 (2006-10-01), None
patent: 2008037626 (2008-04-01), None
patent: 2008068157 (2008-06-01), None
Giordanetto, Bioorg & Med Chem Lett, vol. 17, pp. 4232-4241, 2007.
J.H. Burckhalter, W.H. Edgerton, J. Amer. Chem. Soc., vol. 73, pp. 4837-4839 (1951), XP002469319.
Hoyer et al., Pharmacol. Rev. vol. 46, pp. 157-204 (1994).
Thomas, D. R., Pharmacol. Ther. vol. 111(3) pp. 707-714 (2006).
Francken et al., Eur. J. Pharmacol. vol. 361(2-3) pp. 299-309 (1998).
Rees et al., FEBS Lett. vol. 355 pp. 242-246 (1994).
Doly et al., The Journal of Comparative Neurology vol. 476 pp. 316-329(2004).
Garcia-Ladona et al., 36thAnnual Meeting Soc. Neurosci. (2006) Oct. 14-18th, Atlanta—Abstract 33.1.
Drescher et al., 36thAnnual Meeting Soc. Neurosci. (2006) Oct. 14-18th, Atlanta—Abstract 33.2.
Noda et al., Journal of Neurochemistry vol. 84 (2003) pp. 222-232.
Dubertret et al., Journal of Psychiatric Research vol. 38 (2004) pp. 371-376.
Thomas et al., Neuropharmacology (2006) Sep.; vol. 51(3) pp. 566-577.
Barnes, Neuropharmacology pp. 1083-1152 (1999).
Birkett, NeuroReport, vol. 11 pp. 2017-2020 (2000).
Duncan, Brain Research pp. 178-185 (2000).
Iwata, Mol. Psychiatry pp. 217-219 (2001).
Pasqualetti, Mol. Brain Res. pp. 1-8 (1998).
Wang, Neurosci. Letters pp. 9-12 (2000).
Office Action issued Jul. 1, 2010 in corresponding to U.S. Appl. No. 12/394,083, filed Sep. 21, 2007.
Office Action issued Jul. 1, 2010 in corresponding U.S. Appl. No. 12/394,092, filed Feb. 27, 2009.
Office Action issued Aug. 10, 2010 in corresponding U.S. Appl. No. 12/394,083, filed Sep. 21. 2007.
Acheson, J. Chem. Soc. pp. 4440-4443 (1955).
Sprouse, Synapse pp. 111-118 (2004).

Affiliated with

Also associated with

Rating

Quinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2638422